Owkin

Biotech · Private

Federated learning platform that trains AI models on distributed hospital data for drug discovery without centralizing patient data

Claim this profile

Follows are private to you and power your alerts

Updated · owkin.com

Sector
Biotech
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
11 pending

Capital timeline

No federal awards or Form D filings are on record for this company.

Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.

Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards

Founder? Add funding context

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 11
  • PendingSystems And Methods For Designing Randomized Controlled StudiesUSPTOApplication 18843606
  • PendingSystems And Methods For Identification Of Pancreatic Ductal Adenocarcinoma Molecular SubtypesUSPTOApplication 18558519
  • PendingSystems And Methods For Determining Breast Cancer Prognosis And Associated FeaturesUSPTOApplication 18186111
Show all 11 patent records
  • Systems And Methods For Designing Randomized Controlled StudiesMay 22, 2025 · Application 18843606Pending
  • Systems And Methods For Identification Of Pancreatic Ductal Adenocarcinoma Molecular SubtypesJul 4, 2024 · Application 18558519Pending
  • Systems And Methods For Determining Breast Cancer Prognosis And Associated FeaturesApr 4, 2024 · Application 18186111Pending
  • Systems And Methods For Determining Regions Of Interest In Histology ImagesJan 18, 2024 · Application 18254701Pending
  • Systems And Methods For Determining Breast Cancer Prognosis And Associated FeaturesApplication PCTUS2022043692Pending
  • Systems And Methods For Identification Of Pancreatic Ductal Adenocarcinoma Molecular SubtypesApplication PCTUS2022028140Pending
  • Systems And Methods For Administrating A Federated Learning NetworkApplication PCTUS2021061417Pending
  • Systems And Methods For Determining Regions Of Interest In Histology ImagesApplication PCTUS2021061891Pending
  • Federated External Control Arms Method For Privacy-enhanced Causal Inference On Distributed DataApplication PCTUS2024051768Pending
  • Systems And Methods For Detecting Tertiary Lymphoid StructuresApplication PCTUS2023081687Pending
  • Systems And Methods For Designing Randomized Controlled StudiesApplication PCTUS2023014623Pending
  • NABLA BIO, INC.Similar federal contract value in Biotech · null in contracts
  • VersartisSimilar federal contract value in Biotech · null in contracts
  • Serif BiomedicinesSimilar federal contract value in Biotech · null in contracts
  • PanTeraSimilar federal contract value in Biotech · null in contracts
  • TransposonSimilar federal contract value in Biotech · null in contracts
  • Modal TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .